Company News

November 11, 2013
Back to TopE-mailPrintBookmark and Share

Shares of Endocyte Inc. came roaring back after the company’s executives finally convinced investors there’s a real possibility of getting European approval in the next two months for its first drug. Shares of West Lafayette-based Endocyte soared by nearly 41 percent from its close on Tuesday, just before the company issued its pipeline update, until the end of the week, when the shares closed at $11.64 apiece. Endocyte executives said they expect European regulators to render a decision on its ovarian cancer drug, vintafolide, in December or January. The European regulators have requested an oral presentation by Endocyte, which is usually a sign of some controvery, Wall Street analysts noted. If Endocyte gets the green light, it would start working with its partner, New Jersey-based Merck & Co. Inc., to sell vintalofide next year. Endocyte is also seeking approval for a companion imaging agent. Combined, analysts expect the two products could bring Endoycte as much as $200 million in revenue by 2018.

Two former Eli Lilly and Co. scientists accused of stealing the drugmaker’s trade secrets and passing them to a Chinese company have been released to a halfway house by a federal judge in Indianapolis. The judge, William Lawrence, also acknowledged that the men’s attorneys had “poked sufficient holes” in the case brought by U.S. Attorney Joe Hogsett against the men by suggesting that Guoqing Cao and Shuyu “Dan” Li, only passed on information that Lilly had already put into the public domain. Cao and Li, both of whom live in Carmel, were arrested in October for allegedly emailing sensitive information about nine of Lilly’s experimental drug programs to an employee of Jiangsu Hengrui Medicine Co. Ltd., which is based in China. An executive of Indianapolis-based Lilly estimated during a court hearing that the trade secrets were worth at least $55 million.

Paragon Medical Inc., a Pierceton, Ind.,-based supplier to orthopedic implant companies, has agreed to be acquired by Chicago-based private equity firm Beecken Petty O'Keefe & Co. Financial terms of the transaction, which is expected to close in December, were not disclosed. The company has 950 employees, according to its website.

Testosterone replacement drugs, including one made by Eli Lilly and Co., raised the risk of heart, attack, stroke or death by 29 percent, according to a study of 8,700 men released last week. According to Bloomberg News, the study is the first of a class of drugs, which includes Lilly’s Axiron, as well as AbbVie Inc.’s Androgel. Indianapolis-based Lilly is expected to achieve $168 million in sales this year from Axiron. Androgel could achieve $1.1 billion in sales, according to figures compiled by Bloomberg. An earlier study of testosterone supplements used in elderly males, funded by the U.S. National Institute on Aging and run at Boston Medical Center, was stopped in 2009 because an audit found it caused more heart attacks and high blood pressure. Teresa Shewman, a Lilly spokeswoman, said the company is aware of cardiovascular events in men taking testosterone therapies. “Lilly works with the scientific community and regulatory bodies to further understand and communicate the risks and benefits of testosterone replacement therapy,” Shewman said. “As a company responsible for developing medicines, Lilly is committed to providing advertising that is truthful, accurate and balanced.”


Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.